Fundraising Fox
EuMentis Therapeutics
Newton, US · Founded 2019 · Delaware corporation · 7 employees on LinkedIn · 2 known investors
Find your way into EuMentis Therapeutics
Sign up to see every warm intro you have to EuMentis Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the EuMentis Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
EuMentis Therapeutics develops therapies for neuropsychiatric disorders, targeting selective CNS circuits in the brain. Its lead product, EM-221, is a PDE10A inhibitor in development for schizophrenia and Parkinson's levodopa-induced dyskinesia, with a pipeline addressing conditions such as Alzheimer's-related agitation, treatment-resistant depression, bipolar disorder, and Tourette's.
Founders & leadership
AP
Andrew PearlmanNamed on SEC filing
RM
Randall MarshallNamed on SEC filing
MT
Mark TepperNamed on SEC filing
JL
James LarrickNamed on SEC filing
Investors · 2
Social Startslisted by Social StartsSan Francisco
How we know: Social Starts's portfolio page · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$11.3M disclosed across 4 rounds · 2018–2023
▶$765KraisedJun 2024 · 11 investors · PharmaceuticalsRule 506(b)
▶$765KraisedJun 2024 · 11 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Maryann BrylaDirector
- James LarrickDirector
- Randall MarshallExecutive Officer
- Kim PatrickDirector
- Mark TepperExecutive Officer, Director
- Andrew PearlmanDirector
- Offering amount
- $2M
- Amount sold
- $765K
- Minimum investment
- $20K
- First sale
- Aug 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$4MraisedMar 2023 · 1 investors · PharmaceuticalsRule 506(b)
▶$4MraisedMar 2023 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- mark TepperExecutive Officer, Director
- Kim PatrickDirector
- Randall MarshallExecutive Officer
- Maryann BrylaDirector
- Andrew PearlmanDirector
- James LarrickDirector
- Offering amount
- $20M
- Amount sold
- $4M
- Minimum investment
- $100K
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$5MraisedApr 2022 · 1 investors · PharmaceuticalsRule 506(b)
▶$5MraisedApr 2022 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Randall MarshallExecutive Officer
- Mark TepperExecutive Officer, Director
- Maryann BrylaDirector
- James LarrickDirector
- Amar KapurDirector
- Andrew PearlmanDirector
- Offering amount
- $5M
- Amount sold
- $5M
- Minimum investment
- $5M
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$1.5MraisedSep 2020 · 25 investors · PharmaceuticalsRule 506(b)
▶$1.5MraisedSep 2020 · 25 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Andrew PearlmanDirector
- Randall MarshallExecutive Officer
- Mark TepperExecutive Officer, Director
- James LarrickDirector
- Offering amount
- $3.3M
- Amount sold
- $1.5M
- Minimum investment
- $25K
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does EuMentis Therapeutics do?
- EuMentis Therapeutics develops therapies for neuropsychiatric disorders, targeting selective CNS circuits in the brain. Its lead product, EM-221, is a PDE10A inhibitor in development for schizophrenia and Parkinson's levodopa-induced dyskinesia, with a pipeline addressing conditions such as Alzheimer's-related agitation, treatment-resistant depression, bipolar disorder, and Tourette's.
- Who are EuMentis Therapeutics's investors?
- EuMentis Therapeutics's investors include Joyance Partners, Social Starts.
- How much funding has EuMentis Therapeutics raised?
- EuMentis Therapeutics has disclosed $11.3M raised across 4 rounds.
- Where is EuMentis Therapeutics headquartered?
- EuMentis Therapeutics is headquartered in Newton, US.